Immunome’s $44.9 Initial Public Offering


Goodwin Procter LLP advised Ladenburg Thalmann and Chardan as book-running managers on the deal.

Ladenburg Thalmann and Chardan acted as book-running managers in connection with both Immunome’s (Nasdaq: IMNM) pricing and closing of its upsized initial public offering of 3,250,000 shares of common stock at a public offering price of $12 per share, and the full exercise of the underwriters’ option to purchase an additional 487,500 shares of common stock at the public offering price, resulting in additional gross proceeds of approximately $5.9 million. After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Immunome in the initial public offering was 3,737,500 shares and the gross proceeds were approximately $44.9 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Immunome.

Immunome, Inc. operates as a biotechnology company. The Company develops and commercializes novel therapeutic antibodies and medicines for the treatment of diseases. Immunome serves patients in the State of Pennsylvania.

The Goodwin team was led by Michael Maline (Picture), Michael Rosenberg and Peter Rodas.

Involved fees earner: Michael Maline – Goodwin Procter; Peter Rodas – Goodwin Procter; Michael Rosenberg – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Chardan Capital Markets, LLC; Ladenburg Thalmann & Co.;

Author: Ambrogio Visconti